A cohort study of older adults found a high prevalence of prediabetes, but during more than six years of follow-up, death or regression to normoglycemia was more common than progression to diabetes.
Studies find link between metformin and reduced COVID-19 mortality, mixed results for DPP-4 inhibitors
Prior metformin use was associated with a threefold decrease in mortality from COVID-19 in one study of patients with type 2 diabetes, while three other studies found mixed results on whether dipeptidyl peptidase-4 (DPP-4) inhibitors affect COVID-19 outcomes.
A meta-analysis comparing sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists found differing effects, including that the SGLT-2 inhibitors affected heart failure outcomes while GLP-1 receptor agonists reduced stroke risk.
An article in the February ACP Hospitalist covers how some hospitals have rapidly transitioned inpatient continuous glucose monitoring from research into practice in response to COVID-19.
An ACP Journal Club commentary looked at studies on the effects of canagliflozin in patients with cardiovascular disease and dapagliflozin in patients with peripheral artery disease, concluding that amputation risks are small enough that they needn't play a major role in prescribing decisions.